Platinum-containing heterometallic complexes in cancer therapy: advances and perspectives

Abstract

Platinum-based anticancer drugs are among the most widely used antineoplastics in clinical settings. Their therapeutic applications and outcomes are, however, greatly hampered by drug resistance, systemic toxicity, and the lack...

Anticancer Activities of Re(I) Tricarbonyl and Its Imidazole-Based Ligands: Insight from a Theoretical Approach

“…This success is exemplified by the discovery of cisplatin in 1960 by Barnett Rosenberg . Significantly, it has also conceptualized the modern era of metal-based anticancer drugs, like cisplatin, carboplatin, and oxaliplatin. , In recent years, investigations were carried out with the commitment of researchers and scientists to develop a new anticancer drug consisting of a range of different complexes emanating from Re, Au, Pd, Rh, Os, and Ir metal complexes. − The efficiency of metal-based drugs in cancer therapy cannot be underestimated, as it has recently been used in about 32 out of 78 cancer regimens . Despite these spectacular attributes found in metal-based complexes, they have certain disadvantages as it causes toxic side effects and displays chemotherapeutic resistance. , Various studies on the transition metal rhenium (Re) have been conducted in recent years to develop novel anticancer agents. − Syntheses were carried out on many rhenium complexes, exploring their potential properties as an anticancer agent due to their biological activity of cytotoxicity .…”

“… 3 , 4 In recent years, investigations were carried out with the commitment of researchers and scientists to develop a new anticancer drug consisting of a range of different complexes emanating from Re, Au, Pd, Rh, Os, and Ir metal complexes. 5 − 7 The efficiency of metal-based drugs in cancer therapy cannot be underestimated, as it has recently been used in about 32 out of 78 cancer regimens. 8 Despite these spectacular attributes found in metal-based complexes, they have certain disadvantages as it causes toxic side effects and displays chemotherapeutic resistance.…”

Binuclear platinum(ii) complexes bearing various bridging 1,1′-diphosphinoferrocene ligands as potential anticancer agents: synthesis and biological evaluation

“…2 Despite its high supply and demand as the first clinical anticancer drug, cisplatin has undeniable side effects such as pain, nausea, vomiting, neurotoxicity, nephrotoxicity, and hematological toxicity. [3][4][5][6] Generally, platinum-based compounds which act as soft nucleophiles play an essential role in cancer treatment via Pt-DNA interaction despite their side effects which limit their applications. In recent years, to overcome these limitations numerous strategies such as fluorination of certain bonds, using Pt(IV) instead of Pt(II) centers, multinuclear platinum complexes instead of ligands of mononuclear analogous and chelating nature were designed to optimize platinum-based drugs to approach more effective outcomes.…”

The strongin vitroandvivocytotoxicity of three new cobalt(ii) complexes with 8-methoxyquinoline

“…The Pt-based drug cisplatin and its related complexes comprise the first line of treatment for various types of neoplasms in the fight against cancer. 1–3 However, the clinical application of cisplatin and its analogues has been limited due to their side effects, such as neurotoxicity, drug resistance, emetogenicity, and nephrotoxicity. 4 To overcome these drawbacks, a large number of non-platinum anticancer drugs with less toxicity, greater effectiveness, and higher target specificity have been discovered.…”